These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 4020641)

  • 1. Hepatic elimination--dispersion model.
    Roberts MS; Rowland M
    J Pharm Sci; 1985 May; 74(5):585-7. PubMed ID: 4020641
    [No Abstract]   [Full Text] [Related]  

  • 2. A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics.
    Roberts MS; Rowland M
    J Pharmacokinet Biopharm; 1986 Jun; 14(3):289-308. PubMed ID: 3783448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The area under the curve of metabolites for drugs and metabolites cleared by the liver and extrahepatic organs. Its dependence on the administration route of precursor drug.
    Klippert PJ; Noordhoek J
    Drug Metab Dispos; 1985; 13(1):97-101. PubMed ID: 2858385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of systemic availability from plasma-level data after oral drug administration.
    Perrier D; Gibaldi M; Boyes RN
    J Pharm Pharmacol; 1973 Mar; 25(3):256-7. PubMed ID: 4146327
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic first-pass effects.
    Pang KS
    J Clin Pharmacol; 1986; 26(8):580-2. PubMed ID: 3793946
    [No Abstract]   [Full Text] [Related]  

  • 6. Linear and nonlinear kinetics of drug elimination. I. Kinetics on the basis of a single capacity-limited pathway of elimination with or without simultaneous supply-limited elimination.
    van Ginneken CA; van Rossum JM; Fleuren HL
    J Pharmacokinet Biopharm; 1974 Oct; 2(5):395-415. PubMed ID: 4452943
    [No Abstract]   [Full Text] [Related]  

  • 7. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations.
    Roberts MS; Rowland M
    J Pharmacokinet Biopharm; 1986 Jun; 14(3):227-60. PubMed ID: 3783446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical evaluation of use of effective protein fractions in developing pharmacokinetic models for drug distribution.
    Shen D; Gibaldi M
    J Pharm Sci; 1974 Nov; 63(11):1698-703. PubMed ID: 4372337
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.
    Pang KS; Rowland M
    J Pharmacokinet Biopharm; 1977 Dec; 5(6):625-53. PubMed ID: 599411
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo evaluation of Michaelis-Menten constants of hepatic drug-eliminating systems.
    Pang KS; Rowland M; Tozer TN
    Drug Metab Dispos; 1978; 6(2):197-200. PubMed ID: 26537
    [No Abstract]   [Full Text] [Related]  

  • 11. A new model-independent physiological approach to study hepatic drug clearance and its applications.
    Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):577-90. PubMed ID: 6389376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models of hepatic drug elimination.
    Bass L
    J Pharm Sci; 1983 Oct; 72(10):1229-30. PubMed ID: 6644582
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of unbound drug concentration in blood to discriminate between two models of hepatic drug elimination.
    Morgan DJ; Raymond K
    J Pharm Sci; 1982 May; 71(5):600-2. PubMed ID: 7097517
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary: a physiological approach to hepatic drug clearance.
    Wilkinson GR; Shand DG
    Clin Pharmacol Ther; 1975 Oct; 18(4):377-90. PubMed ID: 1164821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reciprocal actions between the hepatic systems in the biotransformation of drugs and alcohol (author's transl)].
    Bechtel P
    Therapie; 1981; 36(3):257-60. PubMed ID: 7292401
    [No Abstract]   [Full Text] [Related]  

  • 16. Clearance and biologic half-life as indices of intrinsic hepatic metabolism.
    Perrier D; Gibaldi M
    J Pharmacol Exp Ther; 1974 Oct; 191(1):17-24. PubMed ID: 4423599
    [No Abstract]   [Full Text] [Related]  

  • 17. Models of hepatic elimination.
    Weisiger RA
    Hepatology; 1986; 6(2):338-40. PubMed ID: 3007319
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative structure-pharmacokinetics relationships and their importance in drug design, possibilities and limitations.
    Seydel JK
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):571-81. PubMed ID: 6513673
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic factors in hepatic drug oxidation.
    Kalow W; Inaba T
    Prog Liver Dis; 1976; 5():246-58. PubMed ID: 775542
    [No Abstract]   [Full Text] [Related]  

  • 20. Clearance by the liver: current concepts in understanding the hepatic disposition of drugs.
    Larrey D; Branch RA
    Semin Liver Dis; 1983 Nov; 3(4):285-97. PubMed ID: 6359424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.